[1] A. Selzer, Changing aspects of the natural history of valvular aortic stenosis, N. Engl. J. Med. 317 (1987) 91–98, https://doi.org/10.1056/ NEJM198707093170206.
[2] B.R. Lindman, M.-A. Clavel, P. Mathieu, B. Iung, P. Lancellotti, et al., Calcific aortic stenosis, Nat. Rev. Dis. Prim. 2 (2016), 16006, https://doi.org/10.1038/ nrdp.2016.6.
[3] M. Rattazzi, E. Bertacco, A. Del Vecchio, M. Puato, E. Faggin, et al., Aortic valve calcification in chronic kidney disease, Nephrol. Dial. Transplant. 28 (2013) 2968–2976, https://doi.org/10.1093/ndt/gft310.
[4] G.M. London, B. Pannier, S.J. Marchais, A.P. Guerin, Calcification of the aortic valve in the dialyzed patient, J. Am. Soc. Nephrol. 11 (2000) 778–783. http://www.ncbi.nlm.nih.gov/pubmed/10752538.
[5] V. Perkovic, D. Hunt, S. V Griffin, M. du Plessis, G.J. Becker, Accelerated progression of calcific aortic stenosis in dialysis patients, Nephron Clin. Pract. 94 (2004), https://doi.org/10.1159/000071280 c40–c45.
[6] Y. Ahmad, M.F. Bellamy, C.S.R. Baker, Aortic stenosis in dialysis patients, Semin. Dial. 30 (2017) 224–231, https://doi.org/10.1111/sdi.12582.
[7] S. Aljohani, F. Alqahtani, A. Almustafa, K. Boobes, S. Modi, et al., Trends and outcomes of aortic valve replacement in patients with end-stage renal disease on hemodialysis, Am. J. Cardiol. 120 (2017) 1626–1632, https://doi.org/10.1016/j. amjcard.2017.07.063.
[8] Y. Kawase, T. Taniguchi, T. Morimoto, K. Kadota, K. Iwasaki, et al., Severe aortic stenosis in dialysis patients, J. Am. Heart Assoc. 6 (2017), e004961, https://doi. org/10.1161/JAHA.116.004961.
[9] M. Szerlip, A. Zajarias, S. Vemalapalli, M. Brennan, D. Dai, et al., Transcatheter aortic valve replacement in patients with end-stage renal disease, J. Am. Coll. Cardiol. 73 (2019) 2806–2815, https://doi.org/10.1016/j.jacc.2019.03.496.
[10] B. Iung, A. Cachier, G. Baron, D. Messika-Zeitoun, F. Delahaye, et al., Decision- making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur. Heart J. 26 (2005) 2714–2720, https://doi.org/10.1093/eurheartj/ ehi471.
[11] C.M. Otto, R.A. Nishimura, R.O. Bonow, B.A. Carabello, J.P. Erwin, et al., ACC/ AHA guideline for the management of patients with valvular heart disease, J. Am. Coll. Cardiol. 77 (2020), https://doi.org/10.1016/j.jacc.2020.11.018, 2021.
[12] C.M. Otto, B.K. Lind, D.W. Kitzman, B.J. Gersh, D.S. Siscovick, Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly, N. Engl. J. Med. 341 (1999) 142–147, https://doi.org/10.1056/NEJM199907153410302.
[13] S. Coffey, B. Cox, M.J.A. Williams, The prevalence, incidence, progression, and risks of aortic valve sclerosis, J. Am. Coll. Cardiol. 63 (2014) 2852–2861, https:// doi.org/10.1016/j.jacc.2014.04.018.
[14] H. Takahashi, H. Ishii, T. Aoyama, D. Kamoi, H. Kasuga, et al., Association of cardiac valvular calcifications and C-reactive protein with cardiovascular mortality in incident hemodialysis patients: a Japanese cohort study, Am. J. Kidney Dis. 61 (2013) 254–261, https://doi.org/10.1053/j.ajkd.2012.09.007.
[15] P. Raggi, A. Bellasi, C. Gamboa, E. Ferramosca, C. Ratti, et al., All-cause mortality in hemodialysis patients with heart valve calcification, Clin. J. Am. Soc. Nephrol. 6 (2011), https://doi.org/10.2215/CJN.01140211, 1990–1995.
[16] V. Panuccio, R. Tripepi, G. Tripepi, F. Mallamaci, F.A. Benedetto, et al., Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients, Am. J. Kidney Dis. 43 (2004) 479–484, https://doi.org/10.1053/j.ajkd.2003.11.009.
[17] Z. Wang, A. Jiang, F. Wei, H. Chen, Cardiac valve calcification and risk of cardiovascular or all-cause mortality in dialysis patients: a meta-analysis, BMC Cardiovasc. Disord. 18 (2018) 12, https://doi.org/10.1186/s12872-018-0747-y.
[18] M. Li, Z.C. Ye, C.M. Li, W.B. Zhao, H. Tang, et al., The influence of cardiac valvular calcification on all-cause and cardiovascular mortality in maintenance hemodialysis patients, Int. Urol. Nephrol. 52 (2020) 943–951, https://doi.org/ 10.1007/s11255-020-02448-4.
[19] S.M. Gharacholou, B.L. Karon, C. Shub, P.A. Pellikka, Aortic valve sclerosis and clinical outcomes: moving toward a definition, Am. J. Med. 124 (2011) 103–110, https://doi.org/10.1016/j.amjmed.2010.10.012.
[20] H. Baumgartner, J. Hung, J. Bermejo, J.B. Chambers, T. Edvardsen, et al., Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European association of cardiovascular imaging and the American society of echocardiography, J. Am. Soc. Echocardiogr. 30 (2017) 372–392, https://doi.org/10.1016/j.echo.2017.02.009.
[21] R.M. Lang, L.P. Badano, V. Mor-Avi, J. Afilalo, A. Armstrong, et al., Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging, J. Am. Soc. Echocardiogr. 28 (2015) 1–39, https://doi.org/10.1016/j.echo.2014.10.003, e14.
[22] K.A. Hicks, J.E. Tcheng, B. Bozkurt, B.R. Chaitman, D.E. Cutlip, et al., ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials, J. Am. Coll. Cardiol. 66 (2014) 403–469, https://doi.org/10.1016/j. jacc.2014.12.018, 2015.
[23] S.H. Liu, C.Y. Chen, Y.J. Li, H.H. Wu, C.Y. Lin, et al., The value of time-averaged serum high-sensitivity C-reactive protein in prediction of mortality and dropout in peritoneal dialysis patients, Therapeut. Clin. Risk Manag. 13 (2017) 1009–1021, https://doi.org/10.2147/TCRM.S138168.
[24] R.B. Payne, A.J. Little, R.B. Williams, J.R. Milner, Interpretation of serum calcium in patients with abnormal serum proteins, BMJ 4 (1973) 643–646, https://doi.org/ 10.1136/bmj.4.5893.643.
[25] V.T. Nkomo, J.M. Gardin, T.N. Skelton, J.S. Gottdiener, C.G. Scott, et al., Burden of valvular heart diseases: a population-based study, Lancet 368 (2006) 1005–1011, https://doi.org/10.1016/S0140-6736(06)69208-8.
[26] K. Nasir, R. Katz, J. Takasu, D.M. Shavelle, R. Detrano, et al., Ethnic differences between extra-coronary measures on cardiac computed tomography: multi-ethnic study of atherosclerosis (MESA), Atherosclerosis 198 (2008), https://doi.org/ 10.1016/j.atherosclerosis.2007.09.008, 104–114.
[27] K. Nitta, I. Masakane, N. Hanafusa, M. Taniguchi, T. Hasegawa, et al., Annual dialysis data report 2017, JSDT renal data registry, Ren. Replace. Ther. 5 (2019) 53, https://doi.org/10.1186/s41100-019-0248-1.
[28] G.M. Novaro, R. Katz, R.J. Aviles, J.S. Gottdiener, M. Cushman, et al., Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease. The cardiovascular health study, J. Am. Coll. Cardiol. 50 (2007), https:// doi.org/10.1016/j.jacc.2007.07.064, 1992–1998.
[29] C.M. Otto, Why is aortic sclerosis associated with adverse clinical outcomes? J. Am. Coll. Cardiol. 43 (2004) 176–178, https://doi.org/10.1016/j.jacc.2003.10.027.
[30] S. Van Linthout, C. Tscho¨pe, Inflammation – cause or consequence of heart failure or both? Curr. Heart Fail. Rep. 14 (2017) 251–265, https://doi.org/10.1007/ s11897-017-0337-9.
[31] E.R. Maher, G. Young, B. Smyth-Walsh, S. Pugh, J.R. Curtis, Aortic and mitral valve calcification in patients with end-stage renal disease, Lancet 2 (1987) 875–877, https://doi.org/10.1016/S0140-6736(87)91370-5.
[32] M. Hoshina, H. Wada, K. Sakakura, N. Kubo, N. Ikeda, et al., Determinants of progression of aortic valve stenosis and outcome of adverse events in hemodialysis patients, J. Cardiol. 59 (2012) 78–83, https://doi.org/10.1016/j.jjcc.2011.10.003.
[33] P. Michel, Aortic stenosis in chronic renal failure patients treated by dialysis, Nephrol. Dial. Transplant. 13 (1998) 44–48, https://doi.org/10.1093/ndt/13. suppl_4.44.
[34] T.A. Pawade, D.E. Newby, M.R. Dweck, Calcification in aortic stenosis, J. Am. Coll. Cardiol. 66 (2015) 561–577, https://doi.org/10.1016/j.jacc.2015.05.066.
[35] S.J. Cowell, D.E. Newby, R.J. Prescott, P. Bloomfield, J. Reid, et al., A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis, N. Engl. J. Med. 352 (2005) 2389–2397, https://doi.org/10.1056/NEJMoa043876.
[36] A.B. Rossebø, T.R. Pedersen, K. Boman, P. Brudi, J.B. Chambers, et al., Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis, N. Engl. J. Med. 359 (2008) 1343–1356, https://doi.org/10.1056/NEJMoa0804602.
[37] K.L. Chan, K. Teo, J.G. Dumesnil, A. Ni, J. Tam, Effect of lipid lowering with rosuvastatin on progression of aortic stenosis, Circulation 121 (2010) 306–314, https://doi.org/10.1161/CIRCULATIONAHA.109.900027.
[38] D.E. Newby, S.J. Cowell, N.A. Boon, Emerging medical treatments for aortic stenosis: statins, angiotensin converting enzyme inhibitors, or both? Heart 92 (2006) 729–734, https://doi.org/10.1136/hrt.2005.066852.
[39] R. Puri, S.J. Nicholls, M. Shao, Y. Kataoka, K. Uno, et al., Impact of statins on serial coronary calcification during atheroma progression and regression, J. Am. Coll. Cardiol. 65 (2015) 1273–1282, https://doi.org/10.1016/j.jacc.2015.01.036.
[40] T. Nakahara, M.R. Dweck, N. Narula, D. Pisapia, J. Narula, et al., Coronary artery calcification: from mechanism to molecular imaging, JACC cardiovasc, Imaging 10 (2017) 582–593, https://doi.org/10.1016/j.jcmg.2017.03.005.
[41] A.L.S. Chow, S.D. Alhassani, A.M. Crean, G.R. Small, Coronary CT angiography guided medical therapy in subclinical atherosclerosis, J. Clin. Med. 10 (2021) 625, https://doi.org/10.3390/jcm10040625.
[42] F. Antonini-Canterin, M. Hîrs¸u, B.A. Popescu, E. Leiballi, R. Piazza, et al., Stage- related effect of statin treatment on the progression of aortic valve sclerosis and stenosis, Am. J. Cardiol. 102 (2008) 738–742, https://doi.org/10.1016/j. amjcard.2008.04.056.
[43] Z. Hachicha, J.G. Dumesnil, P. Bogaty, P. Pibarot, Paradoxical low-flow, low- gradient severe aortic stenosis despite preserved ejection fraction is associated with higher afterload and reduced survival, Circulation 115 (2007) 2856–2864, https:// doi.org/10.1161/CIRCULATIONAHA.106.668681.
[44] A. Gonz´alez-Mansilla, P. Martinez-Legazpi, A. Prieto, E. Goma´, P. Haurigot, et al., Valve area and the risk of overestimating aortic stenosis, Heart 105 (2019) 911–919, https://doi.org/10.1136/heartjnl-2018-314482.
[45] V. Delgado, M.A. Clavel, R.T. Hahn, L. Gillam, J. Bax, et al., How do we reconcile echocardiography, computed tomography, and hybrid imaging in assessing discordant grading of aortic stenosis severity? JACC Cardiovasc. Imag 12 (2019) 267–282, https://doi.org/10.1016/j.jcmg.2018.11.027.
[46] L.M. Moura, S.F. Ramos, F.J. Pinto, I.M. Barros, F. Rocha-Gonçalves, Analysis of variability and reproducibility of echocardiography measurements in valvular aortic valve stenosis, Rev. Port. Cardiol. 30 (2011) 25–33. http://www.ncbi.nlm. nih.gov/pubmed/21425741.
[47] M. Cristina Di Gioia, R. Gascuena, P. Gallar, G. Cobo, R. Camacho, et al., Echocardiographic findings in haemodialysis patients according to their state of hydration, Nefrologia 37 (2017) 47–53, https://doi.org/10.1016/j.nefro.2016.06.003.